4//SEC Filing
Metzger Michael A 4
Accession 0000950170-25-113659
CIK 0001395937other
Filed
Sep 7, 8:00 PM ET
Accepted
Sep 8, 6:45 PM ET
Size
8.6 KB
Accession
0000950170-25-113659
Insider Transaction Report
Form 4
Metzger Michael A
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2025-09-08$16.41/sh−157,307$2,582,021→ 298,661 total - Exercise/Conversion
Common Stock
2025-09-08$10.90/sh+157,307$1,714,646→ 455,968 total - Exercise/Conversion
Stock options (Right to buy)
2025-09-08+157,307→ 0 totalExercise: $10.90Exp: 2025-09-09→ Common Stock (157,307 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025. Following the sales reported in this Form 4, the Reporting Person has a total of 1,319,634 options to purchase shares of common stock that are vested and immediately exercisable and a total of 651,241 options to purchase shares of common stock that have not yet vested.
- [F2]The sale prices ranged from $16.21 to $17.06.
- [F3]This option is fully vested.
Documents
Issuer
Syndax Pharmaceuticals Inc
CIK 0001395937
Entity typeother
Related Parties
1- filerCIK 0001507220
Filing Metadata
- Form type
- 4
- Filed
- Sep 7, 8:00 PM ET
- Accepted
- Sep 8, 6:45 PM ET
- Size
- 8.6 KB